Why this role exists
Multiply Labs raised $75M Series B on 7 Oct 2026.
Join the Future of Regenerative Medicine Multiply Labs is a robotics company on a mission to solve a significant bottleneck in modern medicine: the manufacturing of life-saving cell therapies. Currently, cell therapies are produced through manual, labor-intensive processes. This keeps costs astronomical—often exceeding $1M per patient—and limits access to only a fraction of those in need. We are revolutionizing this process by building the world’s first modular autonomous robotic factories for pharmaceutical production. Why This Matters We don’t just build robots; we build the infrastructure for the next generation of medicine. Our technology allows biopharma companies to scale production without redesigning their science, drastically lowering regulatory hurdles and bringing costs down to a level where these treatments can actually reach patients. The Stack & The Scale The Mission: Build the world’s best robots to make life-saving therapies accessible to all. The Technology: Advanced robotic orchestration, high-precision automation, and cloud-integrated hardware-software systems. The Location: Headquartered in San Francisco, CA, with offices around the world. This role is based in Italy. The Backing: Supported by premier investors, including Casdin Capital, Lux Capital, and Y Combinator.